Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026

Vaccinex reports new biomarker research and plans for Phase 2 randomized clinical trial of pepinemab in Alzheimer's Disease at the AAIC in July

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.